
Animal Cells as Bioreactors
Terence Cartwright(Author)
Cambridge University Press
Published on 26. August 1994
Book
Hardback
196 pages
978-0-521-41258-2 (ISBN)
Description
Because of their complexity, the new generation of genetically engineered protein drugs can only be made by biotechnological methods, using cultures of animal cells. This book covers all aspects of the technologies needed to turn animal cells into an acceptable and cost-effective tool for drug production. This includes modifying them genetically so that they produce the right product in high yield, getting them to grow reproducibly on an industrial scale, and extracting the required product from them. It also covers biological safety issues, and the verification of the chemical and biological nature of the protein drug produced. The work covers developments in all of these areas and how they all need to be integrated for the design of an effective biotechnological production process. It therefore provides a comprehensive guide to this area of biotechnology.
Reviews / Votes
Review of the hardback: '... provides a useful reference work for all budding biotechnologists.' Wendie Norris, British Society for Development Biology NewsletterMore details
Series
Language
English
Place of publication
Cambridge
United Kingdom
Target group
Professional and scholarly
Illustrations
39 Tables, unspecified; 21 Line drawings, unspecified
Dimensions
Height: 235 mm
Width: 157 mm
Thickness: 15 mm
Weight
443 gr
ISBN-13
978-0-521-41258-2 (9780521412582)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Person
Content
1. Introducing the animal cell as a bioreactor; 2. Yield of recombinant product: engineering cells for maximum expression; 3. The generation of biomass, medium design for animal cell culture, fermenter design for animal cell culture, suspension cultures, immobilized cells, process control; 4. Adjusting cellular metabolism for optimum product yield; 5. Downstream processing; 6. Regulatory aspects of using cells as bioreactors, viral contamination of animal cell derived pharmaceuticals; 7. Overview and conclusions; References; Index.